Key result
U-61, 431F (Ciprostene) administration during and after PTCA resulted in a non-significant reduction in patient restenosis rates (33.3% vs 57.1%) and acute cardiac events compared to control.
Why the study?
Platelets play an important role in restenosis after PTCA, and the effect of a stable PGI2 analogue with platelet inhibitory action on restenosis and acute cardiac events was investigated.
Does the stable PGI2 analogue U-61, 431F prevent acute cardiac events and restenosis in patients undergoing PTCA?
Cohort (n=27)
No
Does the stable PGI2 analogue U-61, 431F prevent acute cardiac events and restenosis in patients undergoing PTCA?
The stable PGI2 analogue U-61, 431F showed a non-significant trend toward reducing restenosis and acute cardiac events in patients undergoing PTCA.
Answers are grounded in this paper and cite their sources.
Does not support ciprostene use to prevent restenosis post-PTCA; leaves open benefit in larger randomized trials.
Mechanism of restenosis after PTCA suggests that platelets play an important role in this response. Since a stable PGI2 analogue, U-61, 431F (group U), has strong platelet inhibitory action, we investigated the preventing effect of U-61, 431F on restenosis and other complications in patients undergoing PTCA. The effect was compared with control (group C). There was no difference in patients background in the two groups. No abrupt coronary occlusion or other cardiac events were observed in group U, but there was two events in group C. Though there was no significant difference in the results between the 2 groups, group U showed lower patient restenosis rate (group U: group C 33.3%:57.1%) and lesion restenosis rate (group U: group C 25.0%:37.5%) based on follow-up angiography. No serious adverse effect was observed in the group U. Thus U-61, 431F may be effective in preventing acute cardiac events during PTCA and restenosis after PTCA.
No takes yet. Share an insight, caveat, or question.
Muramatsu et al. (1990) conducted a cohort in Ischemic heart disease undergoing PTCA (n=27). U-61, 431F (Ciprostene) vs. Control (no antiplatelet agent) was evaluated on Patient restenosis rate (p=not significant). U-61, 431F (Ciprostene) administration during and after PTCA resulted in a non-significant reduction in patient restenosis rates (33.3% vs 57.1%) and acute cardiac events compared to control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: